IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Cytokinetic, Incorporated v Curis, Inc. [2011] APO 66
Patent Application: 780846
Title:Mediators of Hedgehog Signalling Pathways, Compositions and Uses Related Thereto
Patent Applicant: Curis, Inc.
Opponent:Cytokinetics, Incorporated
Delegate:Ms Nicole Howard
Decision Date: 23 August 2011
Hearing Date: 23 May 2011 in Canberra
Catchwords: PATENTS - section 59 - opposition to grant of a patent – claims not novel – claims not fairly based – opposed specification does not anticipate itself – library of compounds publicly available – opposition succeeds – costs awarded against applicant
Representation: Patent applicant: Andrew Fox of Counsel, instructed by Ivan Rajkovic, Patent Attorney of Shelston IP, Sydney
Opponent:Matthew Lucas, Patent Attorney of Davies Collison Cave, Sydney and by William Pickering, Patent Attorney of Davies Collison Cave, Sydney
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 780846
Title:Mediators of Hedgehog Signalling Pathways, Compositions and Uses Related Thereto
Patent Applicant: Curis, Inc.
Date of Decision: 23 August 2011
DECISION
The opposition succeeds on grounds of novelty, fair basis and clarity. Costs awarded against the applicant.
REASONS FOR DECISION
Background
Patent application 780846 (‘hereafter the application’) was filed under the PCT (WO2001/019800) by Curis, Inc. (hereafter ‘Curis’) on 15 September 2000. It claims priority from
· US 60/154 526 filed on 16 September 1999
· US 60/159 412 filed on 14 October 1999
· US 60/162899 filed on 1 November 1999
After several rounds of amendments the specification was accepted on 25 February 2005.
A notice of opposition to grant of a patent was filed on 21 July 2005 by Cytokinetics, Incorporated (hereafter ‘Cytokinetics’), followed by a statement of grounds and particulars (hereafter ‘SGP’) on 21 October 2005. On 12 February 2007 amendments to the SGP were allowed.
Evidence
Evidence in support was completed on 12 October 2007, consisting of Statutory Declarations by
·Associate Professor Joseph Attila Rothnagel dated 26 October 2006 (Rothnagel No. 1) together with Exhibits JAR-1 and JAR-3
·Associate Professor Joseph Attila Rothnagel dated 22 June 2007 (Rothnagel No. 2) together with Exhibits JAR-4 to JAR-6
·Dr Craig Williams dated 28 February 2007 (Williams) together with Exhibits CW-1 to CW-13
·Professor Curt Wentrup dated 31 May 2007 (Wentrup) together with Exhibits CW-1 to CW-8
·Dr William John Pickering dated 15 October 2007 (Pickering) together with Exhibits WJP-1 to WJP-3. WJP-1, WJP-2 and WJP-3 are declarations made by Dr Jeffery T Finer, designated Finer 1, Finer 2 and Finer 3 respectively. The Finer declarations were made in relation to Cytokinetic’s opposition to European Patent No 127268.
Evidence in answer was completed on 15 March 2010, consisting of Statutory Declarations by
·Dr Ivan Alexander Rajkovic dated 10 November 2009 (Rajkovic) together with Exhibit IAR-1 which is a declaration by Frederic de Sauvage (Sauvage). Sauvage further includes Exhibits FD-1 to FD-6.
·Dr William Denny dated 14 January 2010 (Denny) together with Exhibits WAD-1 to WAD-7
·Dr Stephen E Gould dated 9 March 2010 (Gould) together with Exhibits SEG-1 to SEG-6
Evidence in reply was completed on 16 June 2010, consisting of a Statutory Declaration by
Keep reading for free
Create a free CaseChat account to read Cytokinetic, Incorporated v Curis, Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] APO 66
- Decision Date
CaseChat Overview and Summary
The grounds for opposition included lack of novelty, lack of inventive step, lack of manner of manufacture, failure to comply with s.40 (fair basis, clarity), and utility. The court found that the claims 50-63, 67, 71 and 73-75 were not novel due to the public availability of a compound library from ComGenex, Inc. The court also found that claims 50, 51, 53-56, 59-62 and 67 were not novel in light of a published patent application from ChemoCentryx, Inc. The court found that claims 6-9, 11-23, 27, 28, 30-45, 68 and 69 were not fairly based on the specification as filed. The court found that claim 50 was not clear, as it was not evident what was contemplated by variable Z. The court found that the utility of the claims was not established as the compounds within the scope of the claims had been shown to be ineffective in inhibiting the proliferation of human ovarian cancer cells. However, the applicant provided sufficient evidence to explain the results of the experiments, and therefore, inutility was not established.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi